Prohost Observations

As you know COM701 is Compugen’s humanized antibody which binds with high affinity to PVRIG, a novel immune also discovered computationally by Compugen. Binding to PVRIG the firm’s antibody blocks the interaction with its ligand, PVRL2 TIGIT which was also discovered by this small firm.

Early preclinical data suggested that the blockade of PVRIG induces a robust anti-tumor immune response and demonstrates synergistic activity when used in combination with inhibitors of TIGIT and/or PD-1.

Data from Phase 1 study demonstrated that COM701 is well-tolerated in addition to providing signs of anti-tumor activity in a heavily pretreated patient population.

We remind that Compugen has recently announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701 for the treatment of advanced solid tumors in an oral presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I on April 27, 2020 at 11:45 AM EST.

As we have previously stated the presentation is titled, “COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors”. Included in the presentation are updates from the dose-escalation arms of COM701 monotherapy and in combination with Bristol-Myers Squibb’s (BMY) immunotherapy nivolumab.

The presentation will be made available on Compugen’s website at www.cgen.com following the conclusion of the presentation.

Compugen’s predictive computational discovery platforms, which identify drug targets and develop therapeutics in the field of cancer immunotherapy, are becoming the talk of the immunology and cancer immunotherapy worlds.

On April 16, 2020 we wrote, “Compugen might be a small firm, but its predictive computational discovery platform has demonstrated awesome capabilities in discovering new targets for cancer immunotherapy treatments.”

We continue to remind of our opinion that nobody can evaluate biotechnology firms without assessing their scientific and technological capabilities and the promises of their products.    

We are anxiously waiting to hear the news from the Compugen presentation at the 2020 AACR Annual Meeting on April 27th.  

To read more about this firm please use the search engine at our website.